The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Lyophilization Services Market for Biopharmaceuticals by Type of Biologic Lyophilized (Antibodies, Cell and Gene Therapies, Vaccines and Other Biologics), Type of Primary Packaging System (Vials, Syringes, Cartridges, Ampoules and Others) and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    April 2022

  • Pages
    225

  • View Count
    4805

Example Insights

Lyophilization-Services-Market-for-Biopharmaceuticals-Context-thumb Lyophilization-Services-Market-for-Biopharmaceuticals-Biopharmaceuticals-thumb Lyophilization-Services-Market-for-Biopharmaceuticals-Lyophilization-Services-thumb
Lyophilization-Services-Market-for-Biopharmaceuticals-Scale-of-Operation-thumb Lyophilization-Services-Market-for-Biopharmaceuticals-North-America-thumb Lyophilization-Services-Market-for-Biopharmaceuticals-Year-of-Partnership-thumb
Lyophilization-Services-Market-for-Biopharmaceuticals-Year-of-Expansion-thumb Lyophilization-Services-Market-for-Biopharmaceuticals-Biologic-Lyophilized-thumb  

 

Overview

Over the last decade, a steady rise has been observed in the annual number of approvals for various types of biologics (including monoclonal antibodies, cell therapies, recombinant proteins, vaccines and gene therapies). In addition, more than 8,000 biological therapeutics are currently being evaluated in clinical trials, being conducted across the globe. Evidently, biologics have emerged as one of the fastest growing segments in the pharmaceutical industry. Driven by several advantages offered by biologics over small molecules (including high efficacy, target specificity and favorable safety profiles), the biopharmaceutical market is anticipated to witness continued and consistent growth over the next several years. However, there are a variety of challenges associated with such therapies. For instance, biological drugs are inherently less stable as compared to small molecules and, therefore, more prone to physical and chemical degradation. In order to achieve longer and commercially viable shelf lives, players are actively adopting the lyophilization (also known as freeze-drying) technique; it enables the production of stable dry biopharmaceutical formulations. In this context, it is worth highlighting that around 50% of the currently approved biopharmaceuticals are injectables. Of these, about one third of the drug candidates are being lyophilized.

Setting up in-house lyophilization capabilities and operations is an expensive and time-consuming process, which requires specialized lyophilization equipment and expertise. Considering the high capital investment and technical / routine operations-related challenges associated with lyophilization of biopharmaceuticals, a growing number of biologic developers are outsourcing their lyophilization operations to qualified contract manufacturing organizations (CMOs) in order to leverage their capabilities and yield cost savings opportunities. Presently, more than 105 contract manufacturers claim to have the required capabilities to offer lyophilization services for biotherapeutics. In addition, lyophilization service providers are entering into strategic alliances in order to consolidate their presence in this field and enhance existing capabilities to meet the growing demand for biologics. Driven by the increasing preference for outsourcing, continuous growth of the biological therapeutics pipeline and a steady rise in drug approvals, the lyophilization services market for biopharmaceuticals is likely to witness steady growth in the foreseen future.

Scope of the Report

The “Lyophilization Services Market for Biopharmaceuticals: Distribution by Type of Biologic Lyophilized (Antibodies, Cell and Gene Therapies, Vaccines and Other Biologics), Type of Primary Packaging System (Vials, Syringes, Cartridges, Ampoules and Others) and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of companies engaged in offering lyophilization services for biopharmaceuticals. The study features an in-depth analysis of the key drivers and trends related to this domain. Amongst other elements, the report includes:

  • A detailed assessment of the current landscape of companies offering lyophilization services for biopharmaceuticals, along with information on their year of establishment, company size (in terms of employee count), location of headquarters, scale of operation (preclinical, clinical and commercial), regulatory certification / accreditation, type of biologic lyophilized (proteins, antibodies, vaccines, nucleic acids, cell / gene therapies, others and biologics (unspecified)), process of lyophilization (bulk lyophilization and individual lyophilization),  type of primary packaging system (vials, pre-filled syringes, cartridges, ampoules and others) and additional services offered by the firms (lyophilization cycle development and lyophilization cycle optimization).
  • An insightful benchmark analysis of various service providers segregated into three peer groups based on location of their headquarters (North America, Europe, and Asia Pacific and RoW). The companies were further distributed across key geographies, based on their employee count, into three categories, namely small (1-200 employees), mid-sized (201-500 employees) and large / very large (>500 employees), highlighting the top players in this domain, based on their respective capabilities.
  • Elaborate profiles of prominent players offering lyophilization services for biopharmaceuticals, based in North America, Europe and Asia Pacific. Each profile features a brief overview of the company, details related to lyophilization service offerings for biopharmaceuticals, dedicated facilities, recent developments and an informed future outlook.
  • An analysis of the partnerships that have been inked by stakeholders engaged in this domain, covering acquisitions, asset acquisitions, product / technology development agreements, and other related agreements. Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, most active players (in terms of number of partnerships) and regional distribution of the collaborations.
  • A detailed analysis of the recent expansions undertaken by various lyophilization service providers for biopharmaceuticals, based on several relevant parameters, such as year of expansion, type of expansion (capacity expansions, facility expansions and new facility addition), company size (small, mid-sized, large and very large companies), location of headquarters, location of expanded facility, most active players (in terms of number of recent expansions) and geographical distribution.
  • A survey analysis presenting additional insights on lyophilization services offered for biopharmaceuticals, apart from those mentioned on the service provider’s website. Inputs for this chapter were gathered across key parameters, including type of biologic lyophilized, type of primary packaging system, scale of operation, availability of lyophilization cycle development / optimization capabilities and location of dedicated manufacturing facility for lyophilization. Additionally, through the questionnaire we obtained some insights on the likely size of the current market for lyophilization services for biopharmaceuticals.
  • A case study on lyophilization cycle development and optimization services, highlighting the important parameters and techniques required for these processes. Further, the chapter presents the list of players that provide such services for biopharmaceuticals.
  • A case study on alternative approaches to the lyophilization process, such as spray drying, spray freeze drying, atmospheric spray freeze drying and vacuum foam drying.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for lyophilization services market for biopharmaceuticals over the coming decade. We have provided an informed estimate on the likely evolution of the market over the period 2022-2035. The report features a detailed forecast of the overall lyophilization services market for biopharmaceuticals, wherein both the current and upcoming opportunity is segmented across [A] type of biologic lyophilized (antibodies, cell and gene therapies, vaccines and other biologics), [B] type of primary packaging system (vials, syringes, cartridges, ampoules and others) and [C] key geographies (North America, Europe, Asia Pacific, Middle East and North Africa, Latin America and Rest of the world). In order to account for future uncertainties and add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following individuals:

  • Brian Sasaki (Director of Business Development) and Thomas Ingallinera (Vice President of Technical Support), Pharmaceutical International
  • Doreen Coull (Regional Sales Director, Curia)
  • Patrick DePalma (Former Director of CMO Business Development, BioDefense Division, Emergent BioSolutions)
  • Rocio Gonzalez Rodriguez (Head of CDMO Project Management, Liof Pharma)
  • John Shaw (Former Head of Business Development and Marketing, Vibalogics)
  • Sophia Kim (Commercial DP (Depository Participant) Sales / Group Leader, Samsung Biologics)
  • Marianna Tcherpakov (Business Development Manager, Bioserv)
  • Adam Inche (Marketing Manager, Symbiosis Pharmaceutical Services)
  • Adam Viverette (Lyophilization Manager, Patheon)
  • Steven Nail (Principal Scientist, Baxter BioPharma Solutions)

Key Questions Answered

  • Who are the key players engaged in offering lyophilization services for biopharmaceuticals?
  • What is the relative competitiveness of lyophilization service providers for biopharmaceuticals?
  • What type of partnership models are commonly adopted by stakeholders in this industry?
  • What are the different types of expansion initiatives being undertaken by lyophilization service providers for biopharmaceuticals?
  • What are the key market trends and driving factors that are likely to impact this market?
  • How is the current and future market opportunity likely to be distributed across key segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our report. It offers a high-level view of the current state of lyophilization services market for biopharmaceuticals and its likely evolution in the short term, mid-term and long term.

Chapter 3 provides a general overview of the lyophilization process, its historical evolution, underlying principle, as well as associated advantages and disadvantages. The chapter also lays emphasis on lyophilization of biopharmaceuticals, along with various steps involved in the process. Furthermore, it features an elaborate discussion on the lyophilizer, its components and the primary packaging systems used for storage of the lyophilized formulations. It also presents information on lyophilization cycle development and optimization.

Chapter 4 features a detailed review of the current market landscape of around 105 companies offering lyophilization services for biopharmaceuticals. Additionally, it features an in-depth analysis of service providers, based on a number of relevant parameters, such as year of establishment, company size (in terms of employee count) and location of headquarters. The chapter also covers details about scale of operation (preclinical, clinical and commercial), regulatory certification / accreditation, type of biologic lyophilized (proteins, antibodies, vaccines, nucleic acids, cell / gene therapies, others and biologics (unspecified)), process of lyophilization (bulk lyophilization and individual lyophilization), type of primary packaging system (vials, pre-filled syringes, cartridges, ampoules and others) and additional services offered by the firms (lyophilization cycle development and lyophilization cycle optimization).

Chapter 5 presents an insightful benchmark analysis of the lyophilization service providers for biopharmaceuticals, located in North America, Europe, and Asia Pacific and RoW. The companies are further segmented based on their employee count, into three categories, namely small (1-200 employees), mid-sized (201-500 employees) and large / very large (>500 employees) across the key geographies. The analysis compares the service providers on the basis of various parameters, such as number of facilities, scale of operation, number of biologics lyophilized, process of lyophilization and number of primary packaging systems. In the chapter, the top stakeholders in each geography have been plotted on a spider web for their respective capabilities.

Chapter 6 features detailed profiles of the prominent companies that offer lyophilization services for biopharmaceuticals in North America. Each company profile features a brief overview of the company, details related to lyophilization service offerings for biopharmaceuticals, dedicated facilities, recent developments and an informed future outlook.

Chapter 7 features detailed profiles of the prominent companies that offer lyophilization services for biopharmaceuticals in Europe. Each company profile features a brief overview of the company, details related to its lyophilization service offerings for biopharmaceuticals, dedicated facilities, recent developments and an informed future outlook.

Chapter 8 features detailed profiles of the prominent companies that offer lyophilization services for biopharmaceuticals in Asia Pacific. Each company profile features a brief overview of the company, details related to its lyophilization service offerings for biopharmaceuticals, dedicated facilities, recent developments and an informed future outlook.

Chapter 9 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst stakeholders in this domain, in the period 2018 – 2021. Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership model (acquisitions, asset acquisitions, product / technology development agreements and others), most active player(s) (in terms of number of partnerships inked) and regional distribution of the collaborations.

Chapter 10 presents a detailed analysis of the recent expansions undertaken by various lyophilization service providers for biopharmaceuticals, based on several relevant parameters, such as year of expansion, type of expansion (capacity expansions, facility expansions and new facility additions), company size (small, mid-sized, large and very large companies), location of headquarters, location of expanded facility, most active players (in terms of number of recent expansions) and geographical distribution.

Chapter 11 presents insights from the survey conducted for this study. We approached senior stakeholders from various companies involved in providing lyophilization services for biopharmaceuticals. The questionnaire primarily focused on type of biologic lyophilized, type of primary packaging system, scale of operation, availability of lyophilization cycle development / optimization capabilities and location of dedicated manufacturing facility for lyophilization. This helped us develop a deeper understanding on the nature of their services and the associated commercial potential. Additionally, we obtained some insights on the likely size of the current market of lyophilization services for biopharmaceuticals.

Chapter 12 presents a comprehensive market forecast analysis, highlighting the future potential of the market till 2035. We have segregated the current and upcoming opportunity based on [A] type of biologic lyophilized (antibodies, cell and gene therapies, vaccines and other biologics), [B] type of primary packaging system (vials, syringes, cartridges, ampoules and others) and [C] key geographies (North America, Europe, Asia Pacific, Middle East and North Africa, Latin America and Rest of the world). It is worth mentioning that we adopted a top-down approach for this analysis, backing our claims with relevant datapoints and credible inputs from primary research.

Chapter 13 presents elaborate details on lyophilization cycle development and optimization services, highlighting the important parameters and techniques required for these processes and the list of players offering such services for biopharmaceuticals.

Chapter 14 features a case study on alternative methods to the lyophilization process, such as spray drying, spray freeze drying, atmospheric spray freeze drying and vacuum foam drying. It specifically elaborates spray drying, covering information such as step-wise approach, applications of spray drying for biopharmaceuticals, key players providing such services and an informed comparison with lyophilization.

Chapter 15 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 16 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of interview held with Brian Sasaki (Director of Business Development) and Thomas Ingallinera (Vice President of Technical Support), Pharmaceutical International, Doreen Coull (Regional Sales Director, Curia), Patrick DePalma (Former Director of CMO Business Development, BioDefense Division, Emergent BioSolutions), Rocio Gonzalez Rodriguez (Head of CDMO Project Management, Liof Pharma), John Shaw (Former Head of Business Development and Marketing, Vibalogics), Sophia Kim (Commercial DP (Depository Participant) Sales / Group Leader, Samsung Biologics), Marianna Tcherpakov (Business Development Manager, Bioserv), Adam Inche (Marketing Manager, Symbiosis Pharmaceutical Services), Adam Viverette (Lyophilization Manager, Patheon) and Steven Nail (Principal Scientist, Baxter BioPharma Solutions).

Chapter 17 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 18 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Content

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Lyophilization
3.2.1. Historical Evolution
3.2.2. Underlying Principles
3.2.3. Advantages and Disadvantages

3.3. Lyophilization of Biopharmaceuticals
3.3.1. Need for Lyophilization of Biopharmaceuticals
3.3.2. Lyophilization Process
3.3.2.1. Formulation and Filling
3.3.2.2. Freezing
3.3.2.3. Primary Drying
3.3.2.4. Secondary Drying

3.4. Lyophilizer and its Key Components
3.5. Primary Packaging Systems Used for Lyophilization of Biopharmaceuticals

3.6. Lyophilization Cycle Development and Optimization
3.7. Concluding Remarks

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Lyophilization Service Providers for Biopharmaceuticals: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Scale of Operation
4.2.5. Analysis by Regulatory Certification / Accreditation
4.2.6. Analysis by Type of Biologic Lyophilized
4.2.7. Analysis by Process of Lyophilization
4.2.8. Analysis by Type of Primary Packaging System
4.2.9. Analysis by Additional Services Offered

5. BENCHMARK ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Benchmark Analysis: Peer Groups
5.3.1. Benchmark Analysis: North America (Peer Group I)
5.3.2. Benchmark Analysis: North America (Peer Group II)
5.3.3. Benchmark Analysis: North America (Peer Group III)
5.3.4. Benchmark Analysis: Europe (Peer Group IV)
5.3.5. Benchmark Analysis: Europe (Peer Group V)
5.3.6. Benchmark Analysis: Europe (Peer Group VI)
5.3.7. Benchmark Analysis: Asia Pacific and Rest of the World (Peer Group VII)
5.3.8. Benchmark Analysis: Asia Pacific and Rest of the World (Peer Group VIII)

6. COMPANY PROFILES: LYOPHILIZATION SERVICE PROVIDERS FOR BIOPHARMACEUTICALS IN NORTH AMERICA
6.1. Chapter Overview
6.2. Baxter BioPharma Solutions
6.2.1. Company Overview
6.2.2. Lyophilization Service Offerings for Biopharmaceuticals
6.2.3. Dedicated Biopharmaceutical Lyophilization Facilities
6.2.4. Recent Developments and Future Outlook

6.3. Curia
6.3.1. Company Overview
6.3.2. Lyophilization Service Offerings for Biopharmaceuticals
6.3.3. Dedicated Biopharmaceutical Lyophilization Facilities
6.3.4. Recent Developments and Future Outlook

6.4. Emergent BioSolutions
6.4.1. Company Overview
6.4.2. Lyophilization Service Offerings for Biopharmaceuticals
6.4.3. Dedicated Biopharmaceutical Lyophilization Facilities
6.4.4. Recent Developments and Future Outlook

6.5. LSNE Contract Manufacturing
6.5.1. Company Overview
6.5.2. Lyophilization Service Offerings for Biopharmaceuticals
6.5.3. Dedicated Biopharmaceutical Lyophilization Facilities
6.5.4. Recent Developments and Future Outlook

6.6. Lyophilization Technology
6.6.1. Company Overview
6.6.2. Lyophilization Service Offerings for Biopharmaceuticals
6.6.3. Dedicated Biopharmaceutical Lyophilization Facilities
6.6.4. Recent Developments and Future Outlook

7. COMPANY PROFILES: LYOPHILIZATION SERVICE PROVIDERS FOR BIOPHARMACEUTICALS IN EUROPE
7.1. Chapter Overview
7.2. CordenPharma
7.2.1. Company Overview
7.2.2. Lyophilization Service Offerings for Biopharmaceuticals
7.2.3. Dedicated Biopharmaceutical Lyophilization Facilities
7.2.4. Recent Developments and Future Outlook

7.3. Coriolis Pharma
7.3.1. Company Overview
7.3.2. Lyophilization Service Offerings for Biopharmaceuticals
7.3.3. Dedicated Biopharmaceutical Lyophilization Facilities
7.3.4. Recent Developments and Future Outlook
7.4. Northway Biotech
7.4.1. Company Overview
7.4.2. Lyophilization Service Offerings for Biopharmaceuticals
7.4.3. Dedicated Biopharmaceutical Lyophilization Facilities
7.4.4. Recent Developments and Future Outlook

7.5. ProJect Pharmaceutics
7.5.1. Company Overview
7.5.2. Lyophilization Service Offerings for Biopharmaceuticals
7.5.3. Dedicated Biopharmaceutical Lyophilization Facilities
7.5.4. Recent Developments and Future Outlook

7.6. Vetter Pharma
7.6.1. Company Overview
7.6.2. Lyophilization Service Offerings for Biopharmaceuticals
7.6.3. Dedicated Biopharmaceutical Lyophilization Facilities
7.6.4. Recent Developments and Future Outlook

8. COMPANY PROFILES: LYOPHILIZATION SERVICE PROVIDERS FOR BIOPHARMACEUTICALS IN ASIA PACIFIC
8.1. Chapter Overview
8.2. BioZed Engineering
8.2.1. Company Overview
8.2.2. Lyophilization Service Offerings for Biopharmaceuticals
8.2.3. Dedicated Biopharmaceutical Lyophilization Facilities
8.2.4. Recent Developments and Future Outlook

8.3. CinnaGen
8.3.1. Company Overview
8.3.2. Lyophilization Service Offerings for Biopharmaceuticals
8.3.3. Dedicated Biopharmaceutical Lyophilization Facilities
8.3.4. Recent Developments and Future Outlook

8.4. MabPlex
8.4.1. Company Overview
8.4.2. Lyophilization Service Offerings for Biopharmaceuticals
8.4.3. Dedicated Biopharmaceutical Lyophilization Facilities
8.4.4. Recent Developments and Future Outlook

8.5. Samsung Biologics
8.5.1. Company Overview
8.5.2. Lyophilization Service Offerings for Biopharmaceuticals
8.5.3. Dedicated Biopharmaceutical Lyophilization Facilities
8.5.4. Recent Developments and Future Outlook

8.6. WuXi Biologics
8.6.1. Company Overview
8.6.2. Lyophilization Service Offerings for Biopharmaceuticals
8.6.3. Dedicated Biopharmaceutical Lyophilization Facilities
8.6.4. Recent Developments and Future Outlook

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Lyophilization Services for Biopharmaceuticals: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Most Active Players: Analysis by Number of Partnerships
9.3.5. Analysis by Geography
9.3.5.1. Intercontinental and Intracontinental Deals
9.3.5.2. International and Local Deals

10. RECENT EXPANSIONS
10.1. Chapter Overview
10.2. Lyophilization Services Market for Biopharmaceuticals: List of Recent Expansions
10.2.1. Analysis by Year of Expansion
10.2.2. Analysis by Type of Expansion
10.2.3. Analysis by Year and Type of Expansion
10.2.4. Analysis by Company Size and Location of Headquarters
10.2.5. Analysis by Location of Expanded Facility
10.2.6. Active Players: Analysis by Number of Recent Expansions
10.2.7. Analysis by Geography

11. SURVEY ANALYSIS
11.1. Chapter Overview
11.2. Lyophilization Services Market for Biopharmaceuticals: List of Participating Companies
11.2.1. Analysis by Seniority Level of Respondents
11.2.2 Analysis by Type of Biologic Lyophilized
11.2.3. Analysis by Type of Primary Packaging System
11.2.4. Analysis by Scale of Operation
11.2.5. Analysis by Additional Services Offered
11.2.6. Analysis by Location of Lyophilization Facility
11.2.7. Analysis by Share of Lyophilization Operations Outsourced
11.2.8. Analysis by Likely Market Size
11.2.9. Analysis of Likely Market Share by Type of Biologic Lyophilized
11.2.10. Analysis of Likely Market Share by Geography

12. CASE STUDY I: LYOPHILIZATION CYCLE DEVELOPMENT AND OPTIMIZATION
12.1. Chapter Overview
12.2. Lyophilization Cycle Development
12.3. Lyophilization Cycle Optimization
12.4. Lyophilization Cycle Development and Optimization: List of Service Providers
12.4.1. Analysis by Company Size
12.4.2. Analysis by Location of Headquarters
12.4.3. Analysis by Type of Service Offered
12.4.4 Lyophilization Cycle Development and Optimization Service Providers: Company Snapshots

13. CASE STUDY II: ALTERNATIVE APPROACHES TO LYOPHILIZATION
13.1. Chapter Overview
13.2. Alternative Approaches to Lyophilization
13.2.1. Spray Drying
13.2.1.1. Spray Drying Process
13.2.1.2. Applications of Spray Drying
13.2.1.3. Spray Drying of Biopharmaceuticals
13.2.1.4. Spray Drying Service Providers for Biopharmaceuticals
13.2.1.5. Comparison of Lyophilization and Spray Drying

13.2.2. Spray Freeze Drying
13.2.3. Atmospheric Spray Freeze Drying
13.2.4. Vacuum Foam Drying

14. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Forecast Methodology and Key Assumptions
14.3. Global Lyophilization Services Market for Biopharmaceuticals, 2022-2035
14.4. Lyophilization Services Market for Biopharmaceuticals: Distribution by Type of Biologic Lyophilized, 2022 and 2035
14.4.1. Lyophilization Services Market for Antibodies, 2022-2035
14.4.2. Lyophilization Services Market for Cell and Gene Therapies, 2022-2035
14.4.3. Lyophilization Services Market for Vaccines, 2022-2035
14.4.4. Lyophilization Services Market for Other Biologics, 2022-2035

14.5. Lyophilization Services Market for Biopharmaceuticals: Distribution by Type of Primary Packaging System, 2022 and 2035
14.5.1. Lyophilization Services Market for Biopharmaceuticals for Vials, 2022-2035
14.5.2. Lyophilization Services Market for Biopharmaceuticals for Syringes, 2022-2035
14.5.3. Lyophilization Services Market for Biopharmaceuticals for Cartridges, 2022-2035
14.5.4. Lyophilization Services Market for Biopharmaceuticals for Ampoules, 2022-2035
14.5.5. Lyophilization Services Market for Biopharmaceuticals for Other Primary Packaging Systems, 2022-2035

14.6. Lyophilization Services Market for Biopharmaceuticals: Distribution by Geography, 2022 and 2035
14.6.1. Lyophilization Services Market for Biopharmaceuticals in North America, 2022-2035
14.6.2. Lyophilization Services Market for Biopharmaceuticals in Europe, 2022-2035
14.6.3. Lyophilization Services Market for Biopharmaceuticals in Asia Pacific, 2022-2035
14.6.4. Lyophilization Services Market for Biopharmaceuticals in Middle East and North Africa, 2022-2035
14.6.5. Lyophilization Services Market for Biopharmaceuticals in Latin America, 2022-2035
14.6.6. Lyophilization Services Market for Biopharmaceuticals in Rest of the World, 2022-2035

15. CONCLUDING REMARKS

16. EXECUTIVE INSIGHTS
16.1. Chapter Overview
16.2. Pharmaceutical International
16.2.1. Company Snapshot
16.2.2. Interview Transcript: Brian Sasaki, Director of Business Development and Thomas Ingallinera, Vice President of Technical Support

16.3. Curia
16.3.1. Company Snapshot
16.3.2. Interview Transcript: Doreen Coull, Regional Sales Director

16.4. Emergent BioSolutions
16.4.1. Company Snapshot
16.4.2. Interview Transcript: Patrick DePalma, Former Director, CMO Business Development, BioDefense Division

16.5. Liof Pharma
16.5.1. Company Snapshot
16.5.2. Interview Transcript: Rocio Gonzalez Rodriguez, Head of CDMO Project Management

16.6. Vibalogics
16.6.1. Company Snapshot
16.6.2. Interview Transcript: John Shaw, Former Head of Business Development and Marketing

16.7. Samsung Biologics
16.7.1. Company Snapshot
16.7.2. Interview Transcript: Sophia Kim, Commercial DP (Depository Participant) Sales / Group Leader

16.8. Bioserv
16.8.1. Company Snapshot
16.8.2. Interview Transcript: Marianna Tcherpakov, Business Development Manager

16.9. Symbiosis Pharmaceutical Services
16.9.1. Company Snapshot
16.9.2. Interview Transcript: Adam Inche, Marketing Manager

16.10. Patheon
16.10.1. Company Snapshot
16.10.2. Interview Transcript: Adam Viverette, Manager of Lyophilization Operations

16.11. Baxter BioPharma Solutions
16.11.1. Company Snapshot
16.11.2. Interview Transcript: Steven Nail, Principal Scientist

17. APPENDIX 1: TABULATED DATA

18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Partnerships and Collaborations
Figure 2.3 Executive Summary: Recent Expansions
Figure 2.4 Executive Summary: Survey Analysis
Figure 2.5 Executive Summary: Market Forecast
Figure 3.1 Historical Evolution of Lyophilization
Figure 3.2 Phase Diagram of Water
Figure 3.3 Sublimation of Ice Crystals
Figure 3.4 Key Steps Involved in Formulation and Filling of Biopharmaceuticals
Figure 3.5 Key Components of Lyophilizer
Figure 4.1 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Year of Establishment
Figure 4.2 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Company Size
Figure 4.3 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Location of Headquarters
Figure 4.4 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Scale of Operation
Figure 4.5 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Regulatory Certification / Accreditation
Figure 4.6 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Type of Biologic Lyophilized
Figure 4.7 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Process of Lyophilization
Figure 4.8 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Type of Primary Packaging System
Figure 4.9 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Additional Services Offered
Figure 5.1 Benchmark Analysis: Distribution by Company Size
Figure 5.2 Benchmark Analysis: North America (Peer Group I)
Figure 5.3 Benchmark Analysis: North America (Peer Group II)
Figure 5.4 Benchmark Analysis: North America (Peer Group III)
Figure 5.5 Benchmark Analysis: Europe (Peer Group IV)
Figure 5.6 Benchmark Analysis: Europe (Peer Group V)
Figure 5.7 Benchmark Analysis: Europe (Peer Group VI)
Figure 5.8 Benchmark Analysis: Asia Pacific and Rest of the World (Peer Group VII)
Figure 5.9 Benchmark Analysis: Asia Pacific and Rest of the World (Peer Group VIII)
Figure 9.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2021
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 9.4 Most Active Players: Distribution by Number of Partnerships
Figure 9.5 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 9.6 Partnerships and Collaborations: International and Local Deals
Figure 10.1 Recent Expansions: Cumulative Year-wise Trend, 2018-2021
Figure 10.2 Recent Expansions: Distribution by Type of Expansion
Figure 10.3 Recent Expansions: Distribution by Year and Type of Expansion
Figure 10.4 Recent Expansions: Distribution by Company Size and Location of Headquarters
Figure 10.5 Recent Expansions: Distribution by Location of Expanded Facility
Figure 10.6 Recent Expansions: Distribution by Location of Expanded Facility and Type of Expansion
Figure 10.7 Active Players: Distribution by Number of Recent Expansions
Figure 10.8 Recent Expansions: Distribution by Geography
Figure 11.1 Survey Analysis: Distribution by Geographical Location of Respondents
Figure 11.2 Survey Analysis: Distribution by Seniority Levels of Respondents
Figure 11.3 Survey Analysis: Distribution by Type of Biologic Lyophilized
Figure 11.4 Survey Analysis: Distribution by Type of Primary Packaging System
Figure 11.5 Survey Analysis: Distribution by Scale of Operation
Figure 11.6 Survey Analysis: Distribution by Additional Services Offered
Figure 11.7 Survey Analysis: Distribution by Location of Lyophilization Facility
Figure 11.8 Survey Analysis: Distribution by Share of Lyophilization Operations Outsourced
Figure 11.9 Survey Analysis: Distribution by Likely Current Market Size
Figure 11.10 Survey Analysis: Distribution of Likely Market Share by Type of Biologic Lyophilized
Figure 11.11 Survey Analysis: Distribution of Likely Market Share by Geography
Figure 12.1 Lyophilization Cycle Development and Optimization Service Providers: Distribution by Company Size
Figure 12.2 Lyophilization Cycle Development and Optimization Service Providers: Distribution by Location of Headquarters
Figure 12.3 Lyophilization Cycle Development and Optimization Service Providers: Distribution by Type of Service Offered
Figure 13.1 Key Steps Involved in Spray Drying Process
Figure 14.1 Global Lyophilization Services Market for Biopharmaceuticals, 2022-2035 (USD Billion)
Figure 14.2 Lyophilization Services Market for Biopharmaceuticals: Distribution by Type of Biologic Lyophilized, 2022 and 2035 (USD Billion)
Figure 14.3 Lyophilization Services Market for Antibodies, 2022-2035 (USD Billion)
Figure 14.4 Lyophilization Services Market for Cell and Gene Therapies, 2022-2035 (USD Billion)
Figure 14.5 Lyophilization Services Market for Vaccines, 2022-2035 (USD Billion)
Figure 14.6 Lyophilization Services Market for Other Biologics, 2022-2035 (USD Billion)
Figure 14.7 Lyophilization Services Market for Biopharmaceuticals: Distribution by Type of Primary Packaging System, 2022 and 2035 (USD Billion)
Figure 14.8 Lyophilization Services Market for Biopharmaceuticals Stored in Vials, 2022-2035 (USD Billion)
Figure 14.9 Lyophilization Services Market for Biopharmaceuticals Stored in Syringes, 2022- 2035 (USD Billion)
Figure 14.10 Lyophilization Services Market for Biopharmaceuticals Stored in Cartridges, 2022-2035 (USD Billion)
Figure 14.11 Lyophilization Services Market for Biopharmaceuticals Stored in Ampoules, 2022-2035 (USD Billion)
Figure 14.12 Lyophilization Services Market for Biopharmaceuticals Stored in Other Primary Packaging Systems, 2022-2035 (USD Billion)
Figure 14.13 Lyophilization Services Market for Biopharmaceuticals: Distribution by Geography, 2022 and 2035 (USD Billion)
Figure 14.14 Lyophilization Services Market for Biopharmaceuticals in North America, 2022- 2035 (USD Billion)
Figure 14.15 Lyophilization Services Market for Biopharmaceuticals in Europe, 2022- 2035 (USD Billion)
Figure 14.16 Lyophilization Services Market for Biopharmaceuticals in Asia Pacific, 2022- 2035 (USD Billion)
Figure 14.17 Lyophilization Services Market for Biopharmaceuticals in Middle East and North Africa, 2022- 2035 (USD Billion)
Figure 14.18 Lyophilization Services Market for Biopharmaceuticals in Latin America, 2022- 2035 (USD Billion)
Figure 14.19 Lyophilization Services Market for Biopharmaceuticals in Rest of the World, 2022- 2035 (USD Billion)
Figure 15.1 Concluding Remarks: Overall Market Landscape
Figure 15.2 Concluding Remarks: Benchmark Analysis
Figure 15.3 Concluding Remarks: Partnership and Collaborations
Figure 15.4 Concluding Remarks: Recent Expansions
Figure 15.5 Concluding Remarks: Market Forecast

List Of Tables

Table 4.1 List of Lyophilization Service Providers for Biopharmaceuticals
Table 5.1 Benchmark Analysis: Information on Peer Groups
Table 6.1 Leading Lyophilization Service Providers for Biopharmaceuticals in North America
Table 6.2 Baxter BioPharma Solutions: Company Snapshot
Table 6.3 Baxter BioPharma Solutions: Lyophilization Service Offerings for Biopharmaceuticals
Table 6.4 Baxter BioPharma Solutions: Information on Dedicated Biopharmaceutical Lyophilization Facilities
Table 6.5 Baxter BioPharma Solutions: Recent Developments and Future Outlook
Table 6.6 Curia: Company Snapshot
Table 6.7 Curia: Lyophilization Service Offerings for Biopharmaceuticals
Table 6.8 Curia: Information on Dedicated Biopharmaceutical Lyophilization Facilities
Table 6.9 Curia: Recent Developments and Future Outlook
Table 6.10 Emergent BioSolutions: Company Snapshot
Table 6.11 Emergent BioSolutions: Lyophilization Service Offerings for Biopharmaceuticals
Table 6.12 Emergent BioSolutions: Information on Dedicated Biopharmaceutical Lyophilization Facilities
Table 6.13 Emergent BioSolutions: Recent Developments and Future Outlook
Table 6.14 LSNE Contract Manufacturing: Company Snapshot
Table 6.15 LSNE Contract Manufacturing: Lyophilization Service Offerings for Biopharmaceuticals
Table 6.16 LSNE Contract Manufacturing: Information on Dedicated Biopharmaceutical Lyophilization Facilities
Table 6.17 LSNE Contract Manufacturing: Recent Developments and Future Outlook
Table 6.18 Lyophilization Technology: Company Snapshot
Table 6.19 Lyophilization Technology: Lyophilization Service Offerings for Biopharmaceuticals
Table 6.20 Lyophilization Technology: Information on Dedicated Biopharmaceutical Lyophilization Facilities
Table 6.21 Lyophilization Technology: Recent Developments and Future Outlook
Table 7.1 Leading Lyophilization Service Providers for Biopharmaceuticals in Europe
Table 7.2 CordenPharma: Company Snapshot
Table 7.3 CordenPharma: Lyophilization Service Offerings for Biopharmaceuticals
Table 7.4 CordenPharma: Information on Dedicated Biopharmaceutical Lyophilization Facilities
Table 7.5 CordenPharma: Recent Developments and Future Outlook
Table 7.6 Coriolis Pharma: Company Snapshot
Table 7.7 Coriolis Pharma: Lyophilization Service Offerings for Biopharmaceuticals
Table 7.8 Coriolis Pharma: Information on Dedicated Biopharmaceutical Lyophilization Facilities
Table 7.9 Coriolis Pharma: Recent Developments and Future Outlook
Table 7.10 Northway Biotech: Company Snapshot
Table 7.11 Northway Biotech: Lyophilization Service Offerings for Biopharmaceuticals
Table 7.12 Northway Biotech: Information on Dedicated Biopharmaceutical Lyophilization Facilities
Table 7.13 Northway Biotech: Recent Developments and Future Outlook
Table 7.14 ProJect Pharmaceutics: Company Snapshot
Table 7.15 ProJect Pharmaceutics: Lyophilization Service Offerings for Biopharmaceuticals
Table 7.16 ProJect Pharmaceutics: Information on Dedicated Biopharmaceutical Lyophilization Facilities
Table 7.17 Vetter Pharma: Company Snapshot
Table 7.18 Vetter Pharma: Lyophilization Service Offerings for Biopharmaceuticals
Table 7.19 Vetter Pharma: Information on Dedicated Biopharmaceutical Lyophilization Facilities
Table 7.20 Vetter Pharma: Recent Developments and Future Outlook
Table 8.1 Leading Lyophilization Service Providers for Biopharmaceuticals in Asia Pacific
Table 8.2 BioZed Engineering: Company Snapshot
Table 8.3 BioZed Engineering: Lyophilization Service Offerings for Biopharmaceuticals
Table 8.4 BioZed Engineering: Information on Dedicated Biopharmaceutical Lyophilization Facilities
Table 8.5 BioZed Engineering: Recent Developments and Future Outlook
Table 8.6 CinnaGen: Company Snapshot
Table 8.7 CinnaGen: Lyophilization Service Offerings for Biopharmaceuticals
Table 8.8 CinnaGen: Information on Dedicated Biopharmaceutical Lyophilization Facilities
Table 8.9 CinnaGen: Recent Developments and Future Outlook
Table 8.9 MabPlex: Company Snapshot
Table 8.10 MabPlex: Lyophilization Service Offerings for Biopharmaceuticals
Table 8.11 MabPlex: Information on Dedicated Biopharmaceutical Lyophilization Facilities
Table 8.12 MabPlex: Recent Developments and Future Outlook
Table 8.13 Samsung Biologics: Company Snapshot
Table 8.14 Samsung Biologics: Lyophilization Service Offerings for Biopharmaceuticals
Table 8.15 Samsung Biologics: Information on Dedicated Biopharmaceutical Lyophilization Facilities
Table 8.16 Samsung Biologics: Recent Developments and Future Outlook
Table 8.17 WuXi Biologics: Company Snapshot
Table 8.18 WuXi Biologics: Lyophilization Service Offerings for Biopharmaceuticals
Table 8.19 WuXi Biologics: Information on Dedicated Biopharmaceutical Lyophilization Facilities
Table 8.20 WuXi Biologics: Recent Developments and Future Outlook
Table 9.1 Lyophilization Services for Biopharmaceuticals: List of Partnerships and Collaborations, 2018-2021
Table 10.1 Lyophilization Services for Biopharmaceuticals: List of Recent Expansions, 2018-2021
Table 11.1 Lyophilization Services Market for Biopharmaceuticals: List of Respondents
Table 12.1 Lyophilization Cycle Development and Optimization: List of Service Providers
Table 12.2 BSP Pharmaceuticals: Company Snapshot
Table 12.3 CuriRx: Company Snapshot
Table 12.4 GILYOS: Company Snapshot
Table 12.5 Pierre Fabre: Company Snapshot
Table 12.6 Singota Solutions: Company Snapshot
Table 13.1 Spray Drying for Biopharmaceuticals: List of Service Providers
Table 13.2 Comparison of Lyophilization and Spray Drying Process
Table 16.1 Pharmaceutical International: Company Snapshot
Table 16.2 Curia: Company Snapshot
Table 16.3 Emergent BioSolutions: Company Snapshot
Table 16.4 Liof Pharma: Company Snapshot
Table 16.5 Vibalogics: Company Snapshot
Table 16.6 Samsung Biologics: Company Snapshot
Table 16.7 Bioserv: Company Snapshot
Table 16.8 Symbiosis Pharmaceutical Services: Company Snapshot
Table 16.9 Patheon: Company Snapshot
Table 16.10 Baxter BioPharma Solutions: Company Snapshot
Table 17.1 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Year of Establishment
Table 17.2 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Company Size
Table 17.3 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Location of Headquarters
Table 17.4 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Scale of Operation
Table 17.5 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Regulatory Certification / Accreditation
Table 17.6 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Type of Biologic Lyophilized
Table 17.7 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Process of Lyophilization
Table 17.8 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Type of Primary Packaging System
Table 17.9 Lyophilization Service Providers for Biopharmaceuticals: Distribution by Additional Services Offered
Table 17.10 Benchmark Analysis: Asia Pacific and Rest of the World, Peer Group VII
Table 17.11 Benchmark Analysis: Asia Pacific and Rest of the World, Peer Group VIII
Table 17.12 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2021
Table 17.13 Partnerships and Collaborations: Distribution by Type of Partnership
Table 17.14 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 17.15 Most Active Players: Distribution by Number of Partnerships
Table 17.16 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 17.17 Partnerships and Collaborations: International and Local Deals
Table 17.18 Recent Expansions: Cumulative Year-wise Trend, 2018-2021
Table 17.19 Recent Expansions: Distribution by Type of Expansion
Table 17.20 Recent Expansions: Distribution by Year and Type of Expansion
Table 17.21 Recent Expansions: Distribution by Company Size and Location of Headquarters
Table 17.22 Recent Expansions: Distribution by Location of Expanded Facility
Table 17.23 Recent Expansions: Distribution by Location of Expanded Facility and Type of Expansion
Table 17.24 Active Players: Distribution by Number of Recent Expansions
Table 17.25 Recent Expansions: Distribution by Geography
Table 17.26 Survey Analysis: Distribution by Geographical Location of Respondents
Table 17.27 Survey Analysis: Distribution by Seniority Levels of Respondents
Table 17.28 Survey Analysis: Distribution by Type of Biologic Lyophilized
Table 17.29 Survey Analysis: Distribution by Type of Primary Packaging System
Table 17.30 Survey Analysis: Distribution by Scale of Operation
Table 17.31 Survey Analysis: Distribution by Additional Services Offered
Table 17.32 Survey Analysis: Distribution by Location of Lyophilization Facility
Table 17.33 Survey Analysis: Distribution by Share of Lyophilization Operations Outsourced
Table 17.34 Survey Analysis: Distribution by Likely Current Market Size
Table 17.35 Survey Analysis: Distribution of Likely Market Share by Type of Biologic Lyophilized
Table 17.36 Survey Analysis: Distribution Likely Market Share by Geography
Table 17.37 Lyophilization Cycle Development and Optimization Service Providers: Distribution by Company Size
Table 17.38 Lyophilization Cycle Development and Optimization Service Providers: Distribution by Location of Headquarters
Table 17.39 Lyophilization Cycle Development and Optimization Service Providers: Distribution by Type of Service Offered
Table 17.40 Global Lyophilization Services Market for Biopharmaceuticals, 2022-2035 (USD Billion)
Table 17.41 Lyophilization Services Market for Biopharmaceuticals: Distribution by Type of Biologic Lyophilized, 2022 and 2035 (USD Billion)
Table 17.42 Lyophilization Services Market for Antibodies, 2022-2035 (USD Billion)
Table 17.43 Lyophilization Services Market for Cell and Gene Therapies, 2022-2035 (USD Billion)
Table 17.44 Lyophilization Services Market for Vaccines, 2022-2035 (USD Billion)
Table 17.45 Lyophilization Services Market for Other Biologics, 2022-2035 (USD Billion)
Table 17.46 Lyophilization Services Market for Biopharmaceuticals: Distribution by Type of Primary Packaging System, 2022 and 2035 (USD Billion)
Table 17.47 Lyophilization Services Market for Biopharmaceuticals Stored in Vials, 2022-2035 (USD Billion)
Table 17.48 Lyophilization Services Market for Biopharmaceuticals Stored in Syringes, 2022- 2035 (USD Billion)
Table 17.49 Lyophilization Services Market for Biopharmaceuticals Stored in Cartridges, 2022- 2035 (USD Billion)
Table 17.50 Lyophilization Services Market for Biopharmaceuticals Stored in Ampoules, 2022- 2035 (USD Billion)
Table 17.51 Lyophilization Services Market for Biopharmaceuticals Stored in Other Primary Packaging Systems, 2022- 2035 (USD Billion)
Table 17.52 Lyophilization Services Market for Biopharmaceuticals: Distribution by Geography, 2022 and 2035 (USD Billion)
Table 17.53 Lyophilization Services Market for Biopharmaceuticals in North America, 2022- 2035 (USD Billion)
Table 17.54 Lyophilization Services Market for Biopharmaceuticals in Europe, 2022- 2035 (USD Billion)
Table 17.55 Lyophilization Services Market for Biopharmaceuticals in Asia Pacific, 2022- 2035 (USD Billion)
Table 17.56 Lyophilization Services Market for Biopharmaceuticals in Middle East and North Africa, 2022- 2035 (USD Billion)
Table 17.57 Lyophilization Services Market for Biopharmaceuticals in Latin America, 2022- 2035 (USD Billion)
Table 17.58 Lyophilization Services Market for Biopharmaceuticals in Rest of the World, 2022- 2035 (USD Billion)

List Of Companies

The following companies and organizations have been mentioned in the report:

  1. AbbVie
  2. Affinity Biologicals (Acquired by Precision BioLogic)
  3. Affinity Life Sciences
  4. Air Products
  5. Ajinomoto Bio-Pharma Services
  6. Alcami
  7. APTSol 
  8. Arbor Investments
  9. Argonaut Manufacturing Services
  10. Attwill Medical Solutions
  11. Axcellerate Pharma (Acquired by Generic Specialties)
  12. Baccinex
  13. Basic Pharma
  14. Baxter BioPharma Solutions
  15. Berkshire Sterile Manufacturing
  16. BioConnection
  17. Biofortuna
  18. BIOLYPH
  19. Biopharma Group
  20. BioReliance
  21. Bioserv 
  22. BioTechLogic
  23. BioTechnique
  24. BioZed Engineering
  25. Boehringer Ingelheim
  26. Bovogen Biologicals
  27. Bryllan
  28. BSP Pharmaceuticals
  29. Burrard Pharmaceuticals
  30. Canada Peptide
  31. CARBOGEN AMCIS (Acquired by Dishman Pharmaceuticals and Chemicals)
  32. Catalent
  33. Cenexi 
  34. CinnaGen
  35. CoolVacuum (Acquired by Dara Pharma)
  36. CordenPharma
  37. Coriolis Pharma
  38. Curia
  39. CuriRx
  40. Dalton Pharma Services (Acquired by Seikagaku)
  41. Dara Pharmaceutical Equipment
  42. DavosPharma
  43. Emergent BioSolutions
  44. EnWave
  45. Eurofins
  46. Eurogentec
  47. Eurolyo (A Subsidiary of Groupe)
  48. European Medical Contract Manufacturing (EMCM)
  49. FAMAR
  50. Flow Sciences
  51. Fluorogenics (Acquired by New England Biolabs)
  52. Fresenius Kabi 
  53. GEA
  54. GeneMe
  55. GILYOS
  56. Gipharma (Acquired by Advanced Accelerator Applications)
  57. GlaxoSmithKline (GSK)
  58. Goodwin Biotechnology
  59. GP Pharm
  60. Grand River Aseptic Manufacturing (GRAM)
  61. Groupe Berkem
  62. HALIX
  63. HTD Biosystems
  64. Hycult Biotech
  65. IBEX Pharmaceuticals 
  66. IDT Biologika
  67. Integrated DNA Technologies (IDT)
  68. Integrity Bio (Acquired by Curia)
  69. IRISYS (Acquired by Societal CDMO)
  70. Jubilant HollisterStier
  71. KABS Pharmaceutical Services
  72. Kemp Proteins
  73. Kemwell Biopharma
  74. Lab-i-DOSiTECNO Pharma Technologies
  75. Labyrinth BioPharma (Formerly known as AB BioTechnologies)
  76. LakePharma (Acquired by Curia)
  77. Liof Pharma
  78. Lonza
  79. LSNE Contract Manufacturing (Acquired by PCI Pharma Services)
  80. Luina Bio
  81. LYOCONTRACT 
  82. LyoGen (Acquired by Argonaut Manufacturing Services)
  83. LyoHUB
  84. Lyophilization Technology (LTI)
  85. MabPlex
  86. MBU-Technology
  87. Medicago
  88. Miltenyi Biotec
  89. Mycenax Biotech
  90. nanoTools Antibody Technology
  91. National Collection of Industrial, Food and Marine Bacteria (NCIMB)
  92. Nektar Therapeutics 
  93. New England Biolabs (NEB)
  94. Nitto Avecia Pharma Services
  95. Northway Biotech
  96. Oncotec Pharma Produktion
  97. OPTIMA pharma 
  98. Oregon Freeze Dry (Acquired by Arbor Investments)
  99. Parker Freeze Dry
  100. Patheon (Acquired by Thermo Fischer Scientific)
  101. PaxVax
  102. PCI Pharma Services
  103. Pfizer CentreOne
  104. Pharma Gen
  105. Pharmaceutics International
  106. Pierre Fabre
  107. Piramal Pharma Solutions
  108. Precision BioLogic 
  109. Premas Biotech
  110. Profacgen
  111. ProForm Fabrication
  112. ProJect Pharmaceutics
  113. PSC Biotech
  114. PYRAMID Laboratories
  115. Quality BioResources
  116. Recipharm
  117. Rentschler Fill Solutions
  118. Resilience
  119. SafeBridge Consultants
  120. Samsung Biologics
  121. Seikagaku
  122. Sentinel Diagnostics
  123. Singota Solutions
  124. SP Scientific
  125. Sublime Stericeuticals
  126. Symbiosis Pharmaceutical Services
  127. SynCo Bio Partners
  128. SYNERLAB Group
  129. Therapure Biopharma (Acquired by Resilience)
  130. TriPharm Services (Acquired by Alcami)
  131. Vetter Pharma
  132. Vibalogics
  133. VxP Pharma
  134. Wacker Biotech
  135. WuXi Biologics

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com